highly significantP < 0.001
2 ; P = 0.32); across allergen challenge the differences between time‐points were highly significant ( P < 0.001).
2 ; P = 0.32); across allergen challenge the differences between time‐points were highly significant ( P < 0.001).
There was an improvement in all parameters (except nNO) in subjects taking Cet+PE compared with placebo, however this did not achieve significance probably because of the small study size (overall analysis P > 0.07; comparison of active versus placebo P > 0.09).
PNIF showed a trend to fall after allergen challenge and across all treatment groups (Fig. 2 ).
The graphical analysis shows the trend for a treatment separation that did not reach statistical significance but illustrates the lower variability with MRI than with other methods (Table 2 ).
There was a clear trend that suggested a positive treatment effect after combination therapy (Cet+PE); the data showed a reduction in symptom scores, improvement in nasal patency, and MRI end points (Fig. 2 ), although statistical significance was not achieved perhaps because of the small numbers involved ( n = 14).